- Home
- ATYR vs SUIG Comparison
ATYR vs SUIG Comparison
Compare ATYR & SUIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SUIG
- Stock Information
- Founded
- ATYR 2005
- SUIG 2006
- Country
- ATYR United States
- SUIG United States
- Employees
- ATYR 59
- SUIG N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SUIG Finance Companies
- Sector
- ATYR Health Care
- SUIG Finance
- Exchange
- ATYR Nasdaq
- SUIG Nasdaq
- Market Cap
- ATYR 105.8M
- SUIG 569.0M
- IPO Year
- ATYR 2015
- SUIG N/A
- Fundamental
- Price
- ATYR $1.03
- SUIG $4.06
- Analyst Decision
- ATYR Buy
- SUIG
- Analyst Count
- ATYR 6
- SUIG 0
- Target Price
- ATYR $8.88
- SUIG N/A
- AVG Volume (30 Days)
- ATYR 15.6M
- SUIG 1.2M
- Earning Date
- ATYR 11-06-2025
- SUIG 11-11-2025
- Dividend Yield
- ATYR N/A
- SUIG N/A
- EPS Growth
- ATYR N/A
- SUIG 619.34
- EPS
- ATYR N/A
- SUIG 0.24
- Revenue
- ATYR N/A
- SUIG $3,305,884.00
- Revenue This Year
- ATYR $420.85
- SUIG N/A
- Revenue Next Year
- ATYR $1,919.44
- SUIG N/A
- P/E Ratio
- ATYR N/A
- SUIG $17.33
- Revenue Growth
- ATYR N/A
- SUIG 1.77
- 52 Week Low
- ATYR $0.97
- SUIG $1.13
- 52 Week High
- ATYR $7.29
- SUIG $8.66
- Technical
- Relative Strength Index (RSI)
- ATYR 22.25
- SUIG N/A
- Support Level
- ATYR $1.00
- SUIG N/A
- Resistance Level
- ATYR $6.50
- SUIG N/A
- Average True Range (ATR)
- ATYR 0.46
- SUIG 0.00
- MACD
- ATYR -0.51
- SUIG 0.00
- Stochastic Oscillator
- ATYR 1.01
- SUIG 0.00
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.